ENTRY       D10015                      Drug
NAME        Litgenprostucel-L (USAN);
            CG8711
EFFICACY    Antineoplastic
  TYPE      Cellular therapy product
COMMENT     Immunotherapy for the treatment of prostate cancer
            One of two components of a prostate cancer cellular immunotherapy consisting of a prostate adenocarcinoma cell line, LNCaP, that has been modified to secrete Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) and irradiated to prevent tumor cell replication
TARGET      CSF2RA (GMCSFR, CD116) [HSA:1438] [KO:K05066]
  PATHWAY   hsa04060(1438)  Cytokine-cytokine receptor interaction
            hsa04630(1438)  JAK-STAT signaling pathway
            hsa05200(1438)  Pathways in cancer
BRITE       Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokine receptors
               CSF and other factor receptors
                CSF2RA (GMCSFR, CD116)
                 D10015  Litgenprostucel-L (USAN)
DBLINKS     PubChem: 135626736
///
